By Scott Kanowsky Investing.com -- Amgen Inc. (NASDAQ:AMGN) has agreed to buy Horizon Therapeutics PLC (NASDAQ:HZNP) in an all-cash deal that values the biotech firm at about...
Investing.com - Biohaven Pharma reported on Wednesday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations. Biohaven Pharma announced...
EU attempting to revive Iran nuclear deal with market staying pessimistic Crude prices could rebound from oversold conditions but stay off 2022 highs Both Iran, US likely looking...
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company combines a deep understanding of neuroscience, immunology, disease-related biology, advanced chemistry, and expertise in global clinical trials to advance novel therapies for patients. The Company is engaged in delivering new drug approvals for products for diseases such as migraine and schizophrenia, and its research programs, built on a deep understanding of disease-related biology and neuropharmacology, are advancing novel therapies with indications in spinocerebellar ataxia (SCA), amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), epilepsy, depression, obsessive-compulsive disorder (OCD) and neuropathic pain. Its Neuroinnovation portfolio includes a broad pipeline of drug candidates modulating distinct nervous system targets, including Kv7 ion channels (Kv7), glutamate receptors, myeloperoxidase (MPO), myostatin, and transient receptor potential (TRP) channels.
|Average||24.20 (+26.77% Upside)|
|No. of Analysts||5|